PMID- 19839977
OWN - NLM
STAT- MEDLINE
DCOM- 20100107
LR  - 20211020
IS  - 1398-9995 (Electronic)
IS  - 0105-4538 (Linking)
VI  - 64
IP  - 12
DP  - 2009 Dec
TI  - Effects of omalizumab on markers of inflammation in patients with allergic 
      asthma.
PG  - 1728-36
LID - 10.1111/j.1398-9995.2009.02201.x [doi]
AB  - Asthma is a chronic inflammatory disease of the airways in which immunoglobulin E 
      (IgE) plays a key role by activating a variety of inflammatory cells through 
      interactions with FcepsilonRI and FcepsilonRII receptors. The role of IgE in 
      allergic inflammation provided the rationale for developing omalizumab, a 
      humanized monoclonal anti-IgE antibody, for patients with moderate-to-severe or 
      severe allergic asthma. The reductions in circulating levels of IgE resulting 
      from omalizumab treatment leads to reductions in FcepsilonRI expression on mast 
      cells, basophils and dendritic cells. This combined effect results in attenuation 
      of several markers of inflammation, including peripheral and bronchial tissue 
      eosinophilia and levels of granulocyte macrophage colony stimulating factor, 
      interleukin (IL)-2, IL-4, IL-5 and IL-13. By blocking IgE binding to its 
      receptors and diminishing dendritic cell FcepsilonRI receptor expression, 
      omalizumab may also reduce allergen presentation to T cells and the production of 
      Th2 cytokines. The anti-inflammatory effects of omalizumab may, therefore, 
      explain the reductions in asthma exacerbations and symptoms seen in clinical 
      trials in patients with moderate-to-severe or severe, persistent, inadequately 
      controlled allergic asthma.
FAU - Holgate, S
AU  - Holgate S
AD  - Southampton General Hospital, Southampton, UK.
FAU - Smith, N
AU  - Smith N
FAU - Massanari, M
AU  - Massanari M
FAU - Jimenez, P
AU  - Jimenez P
LA  - eng
GR  - G19/34/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20091015
PL  - Denmark
TA  - Allergy
JT  - Allergy
JID - 7804028
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Anti-Asthmatic Agents
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*pharmacology/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*pathology
MH  - Biomarkers/analysis
MH  - Humans
MH  - Inflammation/diagnosis/*drug therapy
MH  - Omalizumab
RF  - 53
EDAT- 2009/10/21 06:00
MHDA- 2010/01/08 06:00
CRDT- 2009/10/21 06:00
PHST- 2009/10/21 06:00 [entrez]
PHST- 2009/10/21 06:00 [pubmed]
PHST- 2010/01/08 06:00 [medline]
AID - ALL2201 [pii]
AID - 10.1111/j.1398-9995.2009.02201.x [doi]
PST - ppublish
SO  - Allergy. 2009 Dec;64(12):1728-36. doi: 10.1111/j.1398-9995.2009.02201.x. Epub 
      2009 Oct 15.